These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
518 related articles for article (PubMed ID: 11502459)
1. The effect of androgen deprivation therapy on health-related quality of life in men with prostate cancer. Lubeck DP; Grossfeld GD; Carroll PR Urology; 2001 Aug; 58(2 Suppl 1):94-100. PubMed ID: 11502459 [TBL] [Abstract][Full Text] [Related]
2. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry. Punnen S; Cowan JE; Chan JM; Carroll PR; Cooperberg MR Eur Urol; 2015 Oct; 68(4):600-8. PubMed ID: 25242555 [TBL] [Abstract][Full Text] [Related]
3. Long-term quality of life in disadvantaged men with prostate cancer on androgen-deprivation therapy. Sevilla C; Maliski SL; Kwan L; Connor SE; Litwin MS Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):237-43. PubMed ID: 22289781 [TBL] [Abstract][Full Text] [Related]
4. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR; Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313 [TBL] [Abstract][Full Text] [Related]
5. Quality of Life after Radical Prostatectomy or Watchful Waiting With or Without Androgen Deprivation Therapy: The SPCG-4 Randomized Trial. Johansson E; Steineck G; Holmberg L; Johansson JE; Nyberg T; Bill-Axelson A; Eur Urol Oncol; 2018 Jun; 1(2):134-142. PubMed ID: 31100237 [TBL] [Abstract][Full Text] [Related]
6. Effect of androgen deprivation therapy on sexual function and bother in men with prostate cancer: A controlled comparison. Donovan KA; Gonzalez BD; Nelson AM; Fishman MN; Zachariah B; Jacobsen PB Psychooncology; 2018 Jan; 27(1):316-324. PubMed ID: 28557112 [TBL] [Abstract][Full Text] [Related]
7. Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. Hoffman KE; Penson DF; Zhao Z; Huang LC; Conwill R; Laviana AA; Joyce DD; Luckenbaugh AN; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Koyama T; Barocas DA JAMA; 2020 Jan; 323(2):149-163. PubMed ID: 31935027 [TBL] [Abstract][Full Text] [Related]
8. Quality of life in prostate cancer patients taking androgen deprivation therapy. Dacal K; Sereika SM; Greenspan SL J Am Geriatr Soc; 2006 Jan; 54(1):85-90. PubMed ID: 16420202 [TBL] [Abstract][Full Text] [Related]
9. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537 [TBL] [Abstract][Full Text] [Related]
10. Induction androgen deprivation therapy before radical prostatectomy for prostate cancer--initial results. Abbas F; Kaplan M; Soloway MS Br J Urol; 1996 Mar; 77(3):423-8. PubMed ID: 8814850 [TBL] [Abstract][Full Text] [Related]
11. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. Garcia-Albeniz X; Chan JM; Paciorek A; Logan RW; Kenfield SA; Cooperberg MR; Carroll PR; Hernán MA Eur J Cancer; 2015 May; 51(7):817-24. PubMed ID: 25794605 [TBL] [Abstract][Full Text] [Related]
12. A prospective study of health-related quality of life outcomes among men treated for intermediate- and high-risk prostate cancer: the impact of primary and secondary therapies. Alsinnawi M; Cullen J; Hurwitz LM; Levie KE; Burns JF; Rosner IL; Brand TC; Stroup S; Sterbis JR; Rice K; Conti G; Porter CR Can J Urol; 2019 Aug; 26(4):9809-9820. PubMed ID: 31469635 [TBL] [Abstract][Full Text] [Related]
13. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. Potosky AL; Reeve BB; Clegg LX; Hoffman RM; Stephenson RA; Albertsen PC; Gilliland FD; Stanford JL J Natl Cancer Inst; 2002 Mar; 94(6):430-7. PubMed ID: 11904315 [TBL] [Abstract][Full Text] [Related]
14. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800 [TBL] [Abstract][Full Text] [Related]
15. Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia. Baade PD; Youlden DR; Gardiner RA; Ferguson M; Aitken JF; Yaxley J; Chambers SK BJU Int; 2012 Dec; 110(11 Pt B):E712-9. PubMed ID: 23017157 [TBL] [Abstract][Full Text] [Related]
16. Patient-perceived satisfaction after definitive treatment for men with high-risk prostate cancer: radical prostatectomy vs. intensity-modulated radiotherapy with androgen deprivation therapy. Yamamoto S; Masuda H; Urakami S; Fujii Y; Sakamoto K; Kozuka T; Oguchi M; Fukui I; Yonese J Urology; 2015 Feb; 85(2):407-13. PubMed ID: 25623703 [TBL] [Abstract][Full Text] [Related]
17. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy. Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664 [TBL] [Abstract][Full Text] [Related]
18. Impact of comorbidity on health-related quality of life in men undergoing radical prostatectomy: data from CaPSURE. Arredondo SA; Elkin EP; Marr PL; Latini DM; DuChane J; Litwin MS; Carroll PR; Urology; 2006 Mar; 67(3):559-65. PubMed ID: 16527580 [TBL] [Abstract][Full Text] [Related]
19. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176 [TBL] [Abstract][Full Text] [Related]
20. Long-term effects of androgen deprivation therapy in prostate cancer patients. Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]